Skip to main content

Vitamin D Insufficiency and Diabetes Risks

Buy Article:

$63.00 plus tax (Refund Policy)

Diabetes is an increasing epidemic; hyperglycemia results from lack of insulin or inadequate insulin secretion following increases in insulin resistance. Huge costs are placed upon sufferers and health providers, aggravated as serious and disabling complications develop. Thus, measures to reduce the diabetic burden are public health concerns. Vitamin D, identified ∼100 years ago, promotes calcium absorption and utilization, preventing and curing rickets and osteomalacia. Calcium is necessary for insulin secretion, suggesting vitamin D may contribute to maintaining insulin secretion. Vitamin D, formed in skin in bright sunshine, is scarce in foodstuffs. Data linking hypovitaminosis D to hyperglycemia, type 2 diabetes (T2DM) and metabolic disorders increasing cardiovascular risk [metabolic ‘syndrome’] has accumulated over ∼40 years. Many mechanisms are known whereby hypovitaminosis D could be causal, e.g. by increasing insulin resistance, reducing insulin secretion and increasing autoimmune or inflammatory damage to pancreatic islets. Major questions still to be answered are whether increasing vitamin D status to the maximum seen in healthy people would reduce the risk of diabetes, the severity of the disease or of its complications, including cardiovascular disease. These questions urgently require answers. If on-going/ planned RCTs confirm causality, maintenance of adequate vitamin D status at the population level by food-fortification or supplementation would be cost-effective measures likely to reduce the burden and costs of diabetes to individuals and health services. Additionally, vitamin D2/3 supplementation is cheap but whether some non-hypercalcemia-inducing analogue may prove safer has not yet been addressed at the population level.





No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: 25-(OH)D; Adiposity; ApoA-1; D binding protein; Diabetes; HOMA-IR; HPLC; MetS; OGTT; RAS; RCTs; RXR; T1DM; T2DM; Type 1 diabetes mellitus; Type 2 diabetes mellitus; UKPDS; anemia; glucose-induced insulin secretion [GISI]; hemodialysis; hemoglobinopathies; homeostasis; hyperglycemia; hyperparathyroidism; hypovitaminosis; insufficiency; insulin; ketoacidosis; metabolic syndrome; metalloproteinases [MMPs]; nonalcoholic fatty liver disease [NAFLD]; osteomalacia; peritoneal dialysis; resistance; retinopathy; secretion; thalassaemia; thermogenesis; vitamin D

Document Type: Research Article

Publication date: 2011-01-01

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more